Following another strong set of FY results, we have revised our forecasts for Aivlosin® and ECO Animal Health as a whole, resulting in an upgrade to FY2019-20e adj EBITDA of 5.5% and 10.5% respectively. We continue to view ECO Animal Health as a core holding in the Animal Health sector, with a solid balance sheet, a positive outlook for Aivlosin® and an attractive medium-term opportunity in swine vaccines. Our valuation implies an intrinsic value of 584p/share.
03 Aug 2018
Margin beat drives EBITDA upgrade
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Margin beat drives EBITDA upgrade
ECO Animal Health Group plc (EAH:LON) | 94.0 0 0.0% | Mkt Cap: 63.7m
- Published:
03 Aug 2018 -
Author:
Jens Lindqvist -
Pages:
3
Following another strong set of FY results, we have revised our forecasts for Aivlosin® and ECO Animal Health as a whole, resulting in an upgrade to FY2019-20e adj EBITDA of 5.5% and 10.5% respectively. We continue to view ECO Animal Health as a core holding in the Animal Health sector, with a solid balance sheet, a positive outlook for Aivlosin® and an attractive medium-term opportunity in swine vaccines. Our valuation implies an intrinsic value of 584p/share.